JAK3 Mutations ID'd in About One-Third of T-Cell Lymphomas

Somatic activating mutation in JAK3 (A572V and A573V) identified in natural killer/T-cell lymphoma

FRIDAY, June 15 (HealthDay News) -- Approximately one-third of patients with natural killer/T-cell lymphoma (NKTCL) harbor somatic-activating Janus kinase 3 (JAK3) mutations, according to a study published online June 15 in Cancer Discovery.

Ghee Chong Koo, Ph.D., from the National Cancer Centre Singapore, and colleagues conducted whole-exome sequencing in four patients with NKTCLs. In 61 additional cases, the prevalence of JAK3 mutations was investigated using Sanger sequencing and high-resolution melt analysis.

In two of the four patients who underwent whole-exome sequencing, the researchers identified JAK3 somatic-activating mutations (A572V and A573V). Further analysis demonstrated that 35.4 percent of cases harbored JAK3 mutations. The JAK3 mutations were suggested to be involved in cytokine-independent JAK/STAT constitutive activation, leading to enhanced growth. Inhibition with the novel pan-JAK inhibitor CP-690550 resulted in dose-dependent reduction of phosphorylated STAT5, reduced cell viability, and increased apoptosis in both JAK3-mutant and wild-type NKTCL cell lines.

"In summary, our studies identified, for the first time, frequent JAK3 mutations in NKTCLs," the authors write. "They also indicated that targeting the JAK/STAT pathway in this disease is a potentially effective therapeutic approach that warrants further investigation."

Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events